SCHEMBL4154886

SCHEMBL4154886

CC(=O)n1c2c(c3cc(Br)ccc31)CCCC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 2/20 0.68
HTR6 P50406 1/20 0.46
PTGS1 P23219 2/20 0.46
PTGS2 P35354 2/20 0.46
TSHR P16473 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
KRAS P01116 3/20 0.44
ALOX5 P09917 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
RXFP1 Q9HBX9 2/20 0.41
HSD17B10 Q99714 1/20 0.41
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
TP53 P04637 1/20 0.41
CREBBP Q92793 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7488308 0.82 CCNB2 (0.53) BAZ2BHTR6PTGS1PTGS2TSHR
SCHEMBL24210090 0.79 ALDH1A1 (0.67) HTR6TSHRALDH1A1KDM4EMEN1
SCHEMBL14717080 0.78 BAZ2B (0.56) BAZ2BALDH1A1KDM4EKRASMAPT
SCHEMBL29865552 0.78 BAZ2B (0.56) BAZ2BALDH1A1KDM4EKRASMAPT
SCHEMBL3861613 0.77 ALOX5 (0.65) BAZ2BPTGS1PTGS2KDM4EKRAS
SCHEMBL17895753 0.76 ALOX5 (0.68) BAZ2BPTGS1PTGS2KDM4EKRAS
SCHEMBL12241734 0.74 ALOX5 (0.60) BAZ2BPTGS1PTGS2ALDH1A1KDM4E
SCHEMBL4727325 0.74 MAPT (0.59) HTR6PTGS1PTGS2ALDH1A1KDM4E
SCHEMBL4970496 0.73 HTR6 (0.40) BAZ2BHTR6PTGS1PTGS2ALDH1A1
SCHEMBL4163005 0.73 DHODH (0.50) BAZ2BHTR6TSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
EP-1824821-A2 CARBAZOLE, CARBOLINE AND INDOLE DERIVATIVES USEFUL IN THE INHIBITION OF VEGF PRODUCTION PTC Therapeutics, Inc. (US) 2007-08-29 EP disclosed
WO-2006058088-A2 CARBAZOLE, CARBOLINE AND INDOLE DERIVATIVES USEFUL IN THE INHIBITION OF VEGF PRODUCTION PTC THERAPEUTICS, INC. (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR BAZ2B 641/4885HTR6 4553/4885PTGS1 112/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR BAZ2B 641/4885HTR6 4553/4885PTGS1 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.